MX374817B - Miembros de union para il-1 beta. - Google Patents

Miembros de union para il-1 beta.

Info

Publication number
MX374817B
MX374817B MX2015005384A MX2015005384A MX374817B MX 374817 B MX374817 B MX 374817B MX 2015005384 A MX2015005384 A MX 2015005384A MX 2015005384 A MX2015005384 A MX 2015005384A MX 374817 B MX374817 B MX 374817B
Authority
MX
Mexico
Prior art keywords
binding members
beta binding
beta
binding
diagnostics
Prior art date
Application number
MX2015005384A
Other languages
English (en)
Spanish (es)
Other versions
MX2015005384A (es
Inventor
Abdijapar Shamshiev
Simone Schmitt
Stefanie Grabulovski
Thorsten Alexander Schäfer
Titus Kretzschmar
Original Assignee
Delenex Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delenex Therapeutics Ag filed Critical Delenex Therapeutics Ag
Publication of MX2015005384A publication Critical patent/MX2015005384A/es
Publication of MX374817B publication Critical patent/MX374817B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
MX2015005384A 2012-11-05 2013-11-05 Miembros de union para il-1 beta. MX374817B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261722532P 2012-11-05 2012-11-05
EP12007503 2012-11-05
PCT/EP2013/073009 WO2014068132A1 (en) 2012-11-05 2013-11-05 Binding members to il-1 beta

Publications (2)

Publication Number Publication Date
MX2015005384A MX2015005384A (es) 2015-10-09
MX374817B true MX374817B (es) 2025-03-06

Family

ID=47146146

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005384A MX374817B (es) 2012-11-05 2013-11-05 Miembros de union para il-1 beta.

Country Status (11)

Country Link
US (5) US9404930B2 (enExample)
EP (2) EP3750917A1 (enExample)
JP (2) JP6333271B2 (enExample)
KR (1) KR102345999B1 (enExample)
CN (1) CN104870015B (enExample)
BR (1) BR112015009892B1 (enExample)
CA (1) CA2888583C (enExample)
MX (1) MX374817B (enExample)
PL (1) PL2914287T3 (enExample)
RU (1) RU2711118C2 (enExample)
WO (2) WO2014068132A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX374817B (es) * 2012-11-05 2025-03-06 Delenex Therapeutics Ag Miembros de union para il-1 beta.
CN106661574B (zh) 2014-08-29 2019-12-06 先锋国际良种公司 涉及油基质的方法和装置
US9078427B1 (en) 2014-08-29 2015-07-14 Pioneer Hi Bred International Inc Method of storing plant embryos
JP6202652B1 (ja) * 2016-12-19 2017-09-27 株式会社ヘルスケアシステムズ 抗エクオール抗体組成物及びその利用
CN107362351B (zh) * 2017-09-04 2020-11-10 上海市儿童医院 Il-36r的拮抗剂在制备镇痛药物中的应用
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
WO2020176210A1 (en) 2019-02-28 2020-09-03 Exxonmobil Chemical Patents Inc. Catalyst compositions and precursors, processes for making the same and syngas conversion processes
TWI793503B (zh) * 2020-01-20 2023-02-21 美商美國禮來大藥廠 抗IL-1β抗體
CA3201637A1 (en) 2020-11-18 2022-05-27 Novartis Ag Bispecific antibodies for use in treatment of nlrc4-gof inflammasomapathy
AU2021405066A1 (en) * 2020-12-23 2023-06-22 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2022136693A1 (en) * 2020-12-23 2022-06-30 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
CN116783218A (zh) * 2020-12-23 2023-09-19 努玛治疗有限公司 具有降低的免疫原性的抗体可变结构域和抗体
CN113908589B (zh) * 2021-10-08 2022-09-27 天津工业大学 一种表面印迹抗体的疏水电荷诱导模式膜层析介质及其制备方法
CN116410331B (zh) * 2021-12-31 2024-01-30 合源生物科技(天津)有限公司 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用
CN116068192A (zh) * 2022-01-24 2023-05-05 中国农业大学 一种检测非洲猪瘟病毒抗体的ELISA检测试剂盒以及protein L的应用
JP2026520185A (ja) * 2023-06-13 2026-06-22 メルク・シャープ・アンド・ドーム・エルエルシー インターロイキン－１ベータを捕捉するための環状ペプチドの使用方法
CN119735676B (zh) * 2023-12-26 2025-12-16 华润生物医药有限公司 抗tslp抗体及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
CN102093477B (zh) 2002-05-22 2014-02-26 艾斯巴技术-诺华有限责任公司 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
JP4538461B2 (ja) * 2003-01-24 2010-09-08 アプライド モレキュラー エボリューション，インコーポレイテッド ヒトＩＬ−１βアンタゴニスト
EP2361933A3 (en) * 2005-01-26 2012-05-02 Amgen Fremont Inc. Antibodies against interleukin-1 beta
EP1891110A2 (en) 2005-06-07 2008-02-27 Esbatech AG STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF-alpha
ES2335232T3 (es) * 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
HRP20130042T1 (hr) * 2008-06-06 2013-03-31 Xoma Technology Ltd. Postupci lijeäśenja reumatoidnog artritisa
GB2461273A (en) 2008-06-24 2009-12-30 Seppo Haekkinen Load monitoring system
GB0811574D0 (en) 2008-06-24 2008-07-30 Trillion Genomics Ltd Characterising planar samples by mass spectrometry
PL2307455T3 (pl) 2008-06-25 2017-09-29 Esbatech, An Alcon Biomedical Research Unit Llc Optymalizacja rozpuszczalności cząsteczek immunowiążących
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
AU2009289547A1 (en) 2008-09-05 2010-03-11 Xoma (Us) Llc Methods for treating or preventing IL-1beta related diseases
WO2012034039A2 (en) 2010-09-10 2012-03-15 Apexigen, Inc. Anti-il-1 beta antibodies and methods of use
MX374817B (es) * 2012-11-05 2025-03-06 Delenex Therapeutics Ag Miembros de union para il-1 beta.

Also Published As

Publication number Publication date
US10077302B2 (en) 2018-09-18
CA2888583A1 (en) 2014-05-08
EP2914287A1 (en) 2015-09-09
CA2888583C (en) 2022-03-29
RU2015120450A (ru) 2016-12-27
CN104870015A (zh) 2015-08-26
US20140134183A1 (en) 2014-05-15
US20200239565A1 (en) 2020-07-30
JP2016503293A (ja) 2016-02-04
JP6333271B2 (ja) 2018-06-06
US20170051054A1 (en) 2017-02-23
US11267884B2 (en) 2022-03-08
US20220220195A1 (en) 2022-07-14
HK1214150A1 (en) 2016-07-22
EP3750917A1 (en) 2020-12-16
EP2914287B1 (en) 2020-03-18
CN104870015B (zh) 2019-07-30
PL2914287T3 (pl) 2020-09-07
KR102345999B1 (ko) 2021-12-30
JP6779252B2 (ja) 2020-11-04
JP2018113988A (ja) 2018-07-26
BR112015009892B1 (pt) 2022-12-27
MX2015005384A (es) 2015-10-09
BR112015009892A2 (pt) 2017-08-22
KR20150079753A (ko) 2015-07-08
US20180362642A1 (en) 2018-12-20
WO2014068132A1 (en) 2014-05-08
WO2015067636A1 (en) 2015-05-14
US9404930B2 (en) 2016-08-02
US10626171B2 (en) 2020-04-21
RU2711118C2 (ru) 2020-01-15

Similar Documents

Publication Publication Date Title
MX2015005384A (es) Miembros de union para il-1 beta.
MX373485B (es) Miembros de unión al factor de necrosis tumoral (tnf) alfa.
BR112018067696A2 (pt) membros de ligação à pd-l1
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
SA520411173B1 (ar) Pd-l1 عوامل ربط ترتبط بـ واستخدامها cd137
HK1215868A1 (zh) 双特异性构建体及其用於治疗多种疾病的用途
PH12015502293A1 (en) Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
EP2558478A4 (en) AT 5 POSITIONS MODIFIED PYRIMIDINES AND THEIR USE
MX2019006362A (es) Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer.
PH12014502527B1 (en) St2 antigen binding proteins
PH12015502819A1 (en) Anti-pd-1 antibody and use thereof
UY34663A (es) Acido nucleico y proteina recombinante del gen de la endotoxina axmi345, vectores, células, composiciones y métodos para proteger plantas
UA112416C2 (uk) Антитіло до fap і способи його застосування
EA201491644A1 (ru) Фармацевтические композиции
MX389093B (es) Composiciones y metodos para la glicosilacion de proteinas.
AR090923A1 (es) Anticuerpos anti-il-23
EP2614085A4 (en) ANTI-IL-1 ANTIBODIES AND METHOD FOR THEIR USE
WO2015058861A8 (en) Bispecific constructs and their use in the treatment of various diseases
BR112015004467A2 (pt) método para controlar a heterogeneidade de proteínas
MX353476B (es) Anticuerpos anti-cxcl13 y metodos para usarlos.
PH12015501687A1 (en) Novel binding proteins from pcsk9
UY34662A (es) Acido nucleico y proteina recombinante del gen de la toxina axmi335, vectores, células, composiciones y métodos para proteger plantas
EA201400089A1 (ru) Конститутивно активные мутанты рецептора абк (абсцизовой кислоты)
MX2015014198A (es) Anticuerpos cuyo objetivo es m-csf.

Legal Events

Date Code Title Description
FG Grant or registration